Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-02-09

FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Austedo (deutetrabenazine) from Teva Neuroscience, Inc., indicating an approved update to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AUSTEDO (deutetrabenazine)

Snippet

SUPPL AP for AUSTEDO (DEUTETRABENAZINE)